Creative Biolabs: Therapeutic Antibody Engineering Unlocks New Avenues in Target Cell Killing

Recent research by the team at Creative Biolabs has led to the development of a platform that integrates a series of innovative therapeutic antibody engineering technologies.
New York, USA - May 27, 2024 - Therapeutic antibody engineering [https://adcc.creative-biolabs.com/therapeutic-antibody-engineering-services.htm] is becoming a crucial area in therapy development for diseases such as cancer, infectious diseases, and autoimmune disorders. This field provides scientists with new methods for targeting and killing cells.

Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg

"Antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are immune effector mechanisms that kill target cells through different pathways. These technologies are a focus of Creative Biolabs' cancer therapy research," according to an expert from Creative Biolabs. "Our CDC/ADCC-enhanced biobetters are developed based on these advanced technologies."

ADCC-Enhanced Therapeutic Antibodies [https://adcc.creative-biolabs.com/category-adcc-enhanced-biobetters-357.htm]

The mechanism of ADCC is the interaction between antibodies and effector cells, such as natural killer cells, which prompts the effector cells to release cytotoxins that kill the target cells. For example, in Creative Biolabs' ADCC-enhanced antibody library, "the enhanced HER2 antibody, by removing the fucose in the Fc region, effectively increases its binding to the Fc receptors on effector cells, thereby boosting ADCC activity," explained the expert.

CDC-Enhanced Therapeutic Antibodies [https://adcc.creative-biolabs.com/category-cdc-enhanced-biobetters-358.htm]

The CDC mechanism involves the interaction between antibodies and the complement system, leading to the initiation of the complement cascade, which ultimately forms the membrane attack complex that lyses target cells. "This process is highly dependent on the protein structure of the Fc region and the activation mechanism of the complement system, which is the focus of our CDC enhancement technology."

Utilizing this mechanism, Creative Biolabs has developed a series of Fc-engineered CDC-enhanced biobetters, such as therapeutic antibodies against CD20, CD38, and IL23. Besides, its customized therapeutic antibody engineering services include antibody engineering, epitope identification, antibody analysis, and functional evaluation, providing tailored solutions for clients.

The following three aspects are considered in Creative Biolabs' antibody optimization designs:

* Safety enhancement engineering techniques targeting humanization, de-immunization, and immune tolerance induction.

* Potentiation engineering to enhance affinity and specificity through Fc engineering and glycosylation modifications.

* Developability enhancement engineering services to achieve lower heterogeneity, higher thermal stability, greater solubility, and higher chemical stability.

"This therapeutic antibody development platform has always been a central focus within Creative Biolabs' diverse research areas, enabling the delivery of comprehensive, one-stop antibody engineering services worldwide," added the expert.

For more information about Creative Biolabs' CDC/ADCC-enhanced product line, please visit https://adcc.creative-biolabs.com.

About

Creative Biolabs is a leading biotechnology company dedicated to developing and providing innovative therapeutic antibody engineering technologies. With a large team of professional scientists, Creative Biolabs has extensive experience and expertise, offering high-quality customized services in antibody engineering, protein engineering, and gene editing.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=creative-biolabs-therapeutic-antibody-engineering-unlocks-new-avenues-in-target-cell-killing]
Phone: 1-631-830-6441
Country: United States
Website: https://adcc.creative-biolabs.com



This release was published on openPR.